ATYR
aTYR PHARMA INC
Next earnings Aug 5, 2026 · consensus $-0.12 EPS
Last earnings -10.0% on 2026-05-15
$0.53
▼ -5.75%$0.53▼ -89.89%
over 1Y
L $0.40EODHDH $6.61
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today-5.8%
1W+12.2%
1M+10.4%
3M-29.9%
YTD-30.5%
1Y-89.9%
Avoid
Conviction
Horizon
Medium (3–12mo)
Street · 15 analysts
Buy
Revenue fell -19.1% YoY.
aTYR PHARMA INC shows $190K in FY2025 revenue (-19.1% YoY), a -39009.5% net margin, and -109.8% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $0.00 | $10.4M | $353K | $235K | $190K |
| Gross profit | — | — | — | — | — |
| Operating income | -$34.0M | -$46.4M | -$54.9M | -$67.9M | -$77.6M |
| Net income | -$33.8M | -$45.3M | -$50.4M | -$64.0M | -$74.1M |
| Diluted EPS | -$1.77 | -$1.60 | -$0.94 | -$0.86 | -$0.80 |
| Net margin | — | -436.5% | -14274.5% | -27243.8% | -39009.5% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$58.0M
EV / EBITDA—
EV / Sales305.2
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-143.3%
FCF yield-120.0%
Quality & risk
ROIC (est.)-72.6%
Free cash flow-$62.1M
Total debt$17.0M
Net cash-$6.26M
Piotroski F-Score2/8
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+10.3%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRed flag in recent filings — delisting notice (2026-06-08). Worth a closer look.
Recent filings
all on EDGAR ↗8-KPeriod ending 2026-06-032026-06-08open ↗SCHEDULE 13G/AFiling2026-06-05open ↗8-KPeriod ending 2026-06-012026-06-01open ↗4Period ending 2026-05-272026-05-28open ↗10-QPeriod ending 2026-03-312026-05-15open ↗8-KPeriod ending 2026-05-152026-05-15open ↗4Period ending 2026-05-112026-05-13open ↗4Period ending 2026-05-112026-05-13open ↗4Period ending 2026-05-112026-05-13open ↗4Period ending 2026-05-112026-05-13open ↗4Period ending 2026-05-112026-05-13open ↗4Period ending 2026-05-112026-05-13open ↗
Frequently asked
- Is aTYR PHARMA INC (ATYR) a buy?
- ATYR currently carries a Avoid rating with 4/5 conviction, derived from its latest SEC filings. Revenue fell -19.1% YoY.
- What is aTYR PHARMA INC's quality score?
- ATYR scores 27.862745098039213/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001339970, latest 10-Q filed 2026-05-15) · EODHD · as of 6/26/2026, 2:07:59 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.